首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1698272

阿片类药物市场机会、成长动力、产业趋势分析及 2025-2034 年预测

Opioid Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

出版日期: 2025年02月24日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球鸦片类药物市场价值为 250 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 1.8%，这主要得益于癌症疼痛、关节炎、纤维肌痛和术后疼痛等慢性疼痛疾病盛行率的上升。随着人口老化加剧以及需要长期疼痛管理的患者数量不断增加，对鸦片类药物的需求持续上升。

阿片类药物产业正在经历重大转型，受到监管变化和不断发展的医疗保健政策的影响。政府和医疗保健提供者正在平衡有效疼痛管理的需求和对鸦片类药物依赖的担忧。虽然各个地区都对阿片类药物处方实施了严格的监管，但具有防滥用特性的鸦片类药物配方的创新正在帮助维持市场成长。此外，製药公司正在投资研究开发更安全的鸦片类药物替代品，同时保持其缓解疼痛的功效。缓释製剂等药物传递系统的进步进一步促进了市场扩张。随着医疗保健提供者采用个人化的疼痛管理方法，阿片类药物市场预计将继续成为製药业的重要领域。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	250亿美元
预测值	296亿美元
复合年增长率	1.8%

市场按药物类型分类，包括羟可酮、氢可酮、吗啡、芬太尼、曲马多和其他鸦片类药物。羟可酮继续占据市场主导地位，2023 年的市值为 87 亿美元，预计到 2034 年将达到 109 亿美元。羟可酮广泛用于治疗中度至重度疼痛，包括术后疼痛和损伤相关疾病，这对其维持市场领先地位起着关键作用。它在癌症疼痛管理中的显着应用，特别是对于化疗患者，进一步巩固了它的重要性。随着对有效缓解疼痛解决方案的需求不断增长，羟可酮仍然是全球治疗方案的重要组成部分。

疼痛管理仍然是最大的应用领域，到 2024 年将占据 74.3% 的市场。阿片类药物广泛用于治疗慢性和重症患者的疼痛。透过与大脑、脊髓和其他部位的鸦片类受体结合，这些药物可以阻断疼痛讯号，为手术后恢復、接受癌症治疗或治疗关节炎等退化性疾病的患者提供必要的缓解。疼痛管理领域对鸦片类药物的持续需求确保了该领域在预测期内将保持其市场主导地位。

2024 年美国鸦片类药物市场价值为 104 亿美元，预计未来十年的复合年增长率为 1.9%。关节炎、癌症和术后恢復等疾病的发生率不断上升，推动了对鸦片类药物疼痛管理解决方案的需求。美国拥有完善的医疗保健基础设施和广泛的鸦片类药物使用，这对市场成长产生了重大影响。随着医疗保健提供者不断寻求有效的疼痛缓解解决方案，该国仍然是整个阿片类药物市场扩张的主要贡献者。随着监管框架的发展和新的疼痛管理策略的出现，阿片类药物市场预计将在美国和其他地区保持稳定成长。

产业生态系统分析
产业衝击力
- 成长动力
  - 慢性疼痛发生率上升
  - 政府支持政策不断增加
  - 阿片类药物製剂的进展
  - 全球外科手术日益增多
- 产业陷阱与挑战
  - 严格的监管要求
  - 成瘾和滥用问题日益严重
成长潜力分析
管道分析
监管格局
波特的分析
PESTEL 分析

第四章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
策略仪表板

第五章：市场估计与预测：按药物类型，2021 年至 2034 年

主要趋势
羟可酮
氢可酮
吗啡
芬太尼
曲马多
其他药物类型

第六章：市场估计与预测：按应用，2021 年至 2034 年

主要趋势
疼痛管理
麻醉
止咳
其他应用

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

主要趋势
口服
注射剂
透皮
其他给药途径

第八章：市场估计与预测：按配销通路，2021 年至 2034 年

主要趋势
医院药房
零售药局
网路药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第十章：公司简介

Allergan
Amneal Pharmaceuticals
AstraZeneca
Camurus AB
Grunenthal
Hikma Pharmaceuticals
Indivior
Mallinckrodt Pharmaceuticals
Pfizer
Purdue Pharma
Rusan Pharma
Sun Pharmaceutical
Teva Pharmaceuticals

简介目录

Product Code: 13222

The Global Opioid Market was valued at USD 25 billion in 2024 and is projected to grow at a CAGR of 1.8% between 2025 and 2034, driven by a rising prevalence of chronic pain conditions such as cancer pain, arthritis, fibromyalgia, and post-surgical pain. With an increasing aging population and a growing number of patients requiring long-term pain management, demand for opioids continues to rise.

The opioid industry is undergoing significant transformation, shaped by both regulatory shifts and evolving healthcare policies. Governments and healthcare providers are balancing the need for effective pain management with concerns about opioid dependency. While strict regulations on opioid prescriptions have been implemented in various regions, innovations in opioid formulations with abuse-deterrent properties are helping sustain market growth. Additionally, pharmaceutical companies are investing in research to develop safer opioid alternatives while maintaining their efficacy in pain relief. Advancements in drug delivery systems, such as extended-release formulations, are further contributing to market expansion. As healthcare providers adopt personalized pain management approaches, the opioid market is expected to remain a crucial segment within the pharmaceutical industry.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$25 Billion
Forecast Value	$29.6 Billion
CAGR	1.8%

The market is categorized by drug type, including oxycodone, hydrocodone, morphine, fentanyl, tramadol, and other opioids. Oxycodone continues to hold a dominant market position, generating USD 8.7 billion in 2023 and is projected to reach USD 10.9 billion by 2034. Oxycodone's widespread use in treating moderate to severe pain, including post-surgical pain and injury-related conditions, plays a key role in its sustained market leadership. Its significant application in cancer pain management, particularly for chemotherapy patients, further solidifies its prominence. As demand for effective pain relief solutions grows, oxycodone remains an essential component of treatment protocols worldwide.

Pain management remains the largest application segment, accounting for a 74.3% market share in 2024. Opioids are extensively used for managing pain in patients suffering from chronic and intense conditions. By binding to opioid receptors in the brain, spinal cord, and other areas, these medications block pain signals, providing essential relief for patients recovering from surgery, undergoing cancer treatments, or managing degenerative diseases like arthritis. This consistent demand for opioids in pain management ensures that the segment will maintain its market dominance over the forecast period.

The U.S. Opioid Market was valued at USD 10.4 billion in 2024 and is projected to grow at a CAGR of 1.9% over the next decade. The increasing prevalence of conditions such as arthritis, cancer, and post-surgical recovery fuels the demand for opioid-based pain management solutions. The U.S. benefits from a well-established healthcare infrastructure and widespread opioid usage, which significantly influences market growth. With healthcare providers continuously seeking effective pain relief solutions, the country remains a key contributor to overall opioid market expansion. As regulatory frameworks evolve and new pain management strategies emerge, the opioid market is expected to sustain steady growth in the U.S. and beyond.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of chronic pain condition
  - 3.2.1.2 Growing supportive government policies
  - 3.2.1.3 Advancements in opioid-based drug formulations
  - 3.2.1.4 Growing surgical procedures globally
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Rising addiction and abuse concerns
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Oxycodone
5.3 Hydrocodone
5.4 Morphine
5.5 Fentanyl
5.6 Tramadol
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Pain management
6.3 Anesthesia
6.4 Cough suppression
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectables
7.4 Transdermal
7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE